Delfi Diagnostics

Delfi Diagnostics is a company dedicated to saving lives through early cancer detection using their innovative fragmentomics technology. Delfi has pioneered breakthroughs in machine learning and fragmentomics by analyzing cell-free DNA fragments from simple liquid biopsy blood samples to support early-stage cancer detection. Their scalable approach allows them to quickly scan millions of data points to identify previously unrecognized cancer-associated DNA fragments. Delfi Diagnostics collaborates with leading cancer biology, bioinformatics, and machine learning experts to advance their technology. The company has initiated a large-scale clinical trial, CASCADE-LUNG, to validate the effectiveness of its approach.